{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:57:04Z","timestamp":1791593824387,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2022KY506"],"award-info":[{"award-number":["2022KY506"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Zhejiang Provincial Nature Science Foundation of China","award":["LQ23H090019"],"award-info":[{"award-number":["LQ23H090019"]}]},{"name":"Traditional Chinese Medicine Science and technology of Zhejiang Province","award":["2024ZL291"],"award-info":[{"award-number":["2024ZL291"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Efgartigimod, a neonatal Fc receptor inhibitor that accelerates IgG degradation, remains understudied in treatment of Guillain-Barr\u00e9 Syndrome (GBS). This study aimed to evaluate the efficacy and safety of efgartigimod in GBS patients. A retrospective analysis included 17 GBS patients (5 patients treated by efgartigimod, 8 patients treated by IVIg, 4 patients treated by PE). Primary outcome is time to a one-point improvement in GBS-DS and time to regain unaided walking ability. GBS-DS score, Inflammatory Neuropathy Cause and Treatment (INCAT) disability score, Medical Research Council (MRC) scores, the proportions of patients with INCAT score\u2009\u2264\u20092 and those achieving full MRC score were recorded at baseline and at 1 week, 1 month, and 3 months post-treatment. Adverse reactions were monitored throughout the treatment period. The patients treated by efgartigimod demonstrated significantly faster improvement of 1-point on the GBS-DS (4.00 days vs. IVIg: 7.00 days, PE: 11.50 days;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.033) and higher proportions of patients with INCAT scores\u2009\u2264\u20092 (80% vs. 12.5% [IVIg], 25% [PE];\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.039) and full MRC scores (80% vs. 12.5% [IVIg];\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.045) at 1 week. Adverse events were mild (20% vs.50% PE). Efgartigimod offers rapid symptom relief and functional recovery in GBS compared to IVIg and PE. These findings highlight its potential as a novel therapeutic option.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-44163-7","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T02:56:02Z","timestamp":1773888962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Rapid neurological recovery in Guillain-Barr\u00e9 syndrome treated with efgartigimod"],"prefix":"10.1038","volume":"16","author":[{"given":"Yifan","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunyuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunrong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manman","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8754-3677","authenticated-orcid":false,"given":"Yiqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"44163_CR1","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/ana.410380214","volume":"38","author":"I Illa","year":"1995","unstructured":"Illa, I. et al. Acute axonal Guillain-Barre syndrome with IgG antibodies against motor axons following parenteral gangliosides. Ann. Neurol. 38, 218\u2013224. https:\/\/doi.org\/10.1002\/ana.410380214 (1995).","journal-title":"Ann. Neurol."},{"key":"44163_CR2","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/tmi.13181","volume":"24","author":"VK Wachira","year":"2019","unstructured":"Wachira, V. K., Peixoto, H. M. & de Oliveira, M. R. F. Systematic review of factors associated with the development of Guillain-Barre syndrome 2007\u20132017: what has changed? Trop. Med. Int. Health. 24, 132\u2013142. https:\/\/doi.org\/10.1111\/tmi.13181 (2019).","journal-title":"Trop. Med. Int. Health"},{"key":"44163_CR3","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/ene.13569","volume":"25","author":"N Matsui","year":"2018","unstructured":"Matsui, N. et al. Guillain-Barre syndrome in a local area in Japan, 2006\u20132015: an epidemiological and clinical study of 108 patients. Eur. J. Neurol. 25, 718\u2013724. https:\/\/doi.org\/10.1111\/ene.13569 (2018).","journal-title":"Eur. J. Neurol."},{"key":"44163_CR4","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.3201\/eid1707.102031","volume":"17","author":"Z Islam","year":"2011","unstructured":"Islam, Z. et al. High incidence of Guillain-Barre syndrome in children, Bangladesh. Emerg. Infect. Dis. 17, 1317\u20131318. https:\/\/doi.org\/10.3201\/eid1707.102031 (2011).","journal-title":"Emerg. Infect. Dis."},{"key":"44163_CR5","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/S0140-6736(21)00517-1","volume":"397","author":"N Shahrizaila","year":"2021","unstructured":"Shahrizaila, N., Lehmann, H. C. & Kuwabara, S. Guillain-Barre syndrome. Lancet 397, 1214\u20131228. https:\/\/doi.org\/10.1016\/S0140-6736(21)00517-1 (2021).","journal-title":"Lancet"},{"key":"44163_CR6","doi-asserted-by":"publisher","unstructured":"Hughes, R. A., Swan, A. V. & van Doorn, P. A. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev 2014, CD002063 (2014). https:\/\/doi.org\/10.1002\/14651858.CD002063.pub6","DOI":"10.1002\/14651858.CD002063.pub6"},{"key":"44163_CR7","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1586\/ern.09.81","volume":"9","author":"A Schroder","year":"2009","unstructured":"Schroder, A., Linker, R. A. & Gold, R. Plasmapheresis for neurological disorders. Expert Rev. Neurother. 9, 1331\u20131339. https:\/\/doi.org\/10.1586\/ern.09.81 (2009).","journal-title":"Expert Rev. Neurother."},{"key":"44163_CR8","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/ana.410220612","volume":"22","author":"Efficiency of plasma","year":"1987","unstructured":"Efficiency of plasma. exchange in Guillain-Barre syndrome: role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barre syndrome. Ann. Neurol. 22, 753\u2013761. https:\/\/doi.org\/10.1002\/ana.410220612 (1987).","journal-title":"Ann. Neurol."},{"key":"44163_CR9","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","volume":"326","author":"FG van der Meche","year":"1992","unstructured":"van der Meche, F. G. & Schmitz, P. I. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl. J. Med. 326, 1123\u20131129. https:\/\/doi.org\/10.1056\/NEJM199204233261705 (1992).","journal-title":"N Engl. J. Med."},{"key":"44163_CR10","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1212\/wnl.43.5.872","volume":"43","author":"DN Irani","year":"1993","unstructured":"Irani, D. N., Cornblath, D. R., Chaudhry, V., Borel, C. & Hanley, D. F. Relapse in Guillain-Barre syndrome after treatment with human immune globulin. Neurology 43, 872\u2013875. https:\/\/doi.org\/10.1212\/wnl.43.5.872 (1993).","journal-title":"Neurology"},{"key":"44163_CR11","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1212\/wnl.43.5.1034","volume":"43","author":"LH Castro","year":"1993","unstructured":"Castro, L. H. & Ropper, A. H. Human immune globulin infusion in Guillain-Barre syndrome: worsening during and after treatment. Neurology 43, 1034\u20131036. https:\/\/doi.org\/10.1212\/wnl.43.5.1034 (1993).","journal-title":"Neurology"},{"key":"44163_CR12","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1212\/wnl.62.9.1653-a","volume":"62","author":"N Latov","year":"2004","unstructured":"Latov, N. Practice parameter: immunotherapy for Guillain-Barre syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 62, 1653\u20131654. https:\/\/doi.org\/10.1212\/wnl.62.9.1653-a (2004). author reply 1654.","journal-title":"Neurology"},{"key":"44163_CR13","doi-asserted-by":"publisher","unstructured":"Chevret, S., Hughes, R. A. & Annane, D. Plasma exchange for Guillain-Barre syndrome. Cochrane Database Syst Rev 2, CD001798 (2017). https:\/\/doi.org\/10.1002\/14651858.CD001798.pub3","DOI":"10.1002\/14651858.CD001798.pub3"},{"key":"44163_CR14","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1001\/jama.291.19.2367","volume":"291","author":"MC Dalakas","year":"2004","unstructured":"Dalakas, M. C. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 291, 2367\u20132375. https:\/\/doi.org\/10.1001\/jama.291.19.2367 (2004).","journal-title":"JAMA"},{"key":"44163_CR15","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","volume":"82","author":"YA Heo","year":"2022","unstructured":"Heo, Y. A. & Efgartigimod First Approval Drugs 82, 341\u2013348 https:\/\/doi.org\/10.1007\/s40265-022-01678-3 (2022).","journal-title":"First Approval Drugs"},{"key":"44163_CR16","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri2155","volume":"7","author":"DC Roopenian","year":"2007","unstructured":"Roopenian, D. C. & Akilesh, S. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7, 715\u2013725. https:\/\/doi.org\/10.1038\/nri2155 (2007).","journal-title":"Nat. Rev. Immunol."},{"key":"44163_CR17","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard, J. F. Jr. et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 20, 526\u2013536. https:\/\/doi.org\/10.1016\/S1474-4422(21)00159-9 (2021).","journal-title":"Lancet Neurol."},{"key":"44163_CR18","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/bjd.20782","volume":"186","author":"M Goebeler","year":"2022","unstructured":"Goebeler, M. et al. Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial. Br. J. Dermatol. 186, 429\u2013439. https:\/\/doi.org\/10.1111\/bjd.20782 (2022).","journal-title":"Br. J. Dermatol."},{"key":"44163_CR19","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1016\/S0140-6736(23)01460-5","volume":"402","author":"CM Broome","year":"2023","unstructured":"Broome, C. M. et al. Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 402, 1648\u20131659. https:\/\/doi.org\/10.1016\/S0140-6736(23)01460-5 (2023).","journal-title":"Lancet"},{"key":"44163_CR20","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1474-4422(24)00309-0","volume":"23","author":"JA Allen","year":"2024","unstructured":"Allen, J. A. et al. Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 23, 1013\u20131024. https:\/\/doi.org\/10.1016\/S1474-4422(24)00309-0 (2024).","journal-title":"Lancet Neurol."},{"key":"44163_CR21","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1007\/s00415-024-12321-4","volume":"271","author":"H Zhang","year":"2024","unstructured":"Zhang, H. et al. Efgartigimod in the treatment of Guillain-Barre syndrome. J. Neurol. 271, 3506\u20133511. https:\/\/doi.org\/10.1007\/s00415-024-12321-4 (2024).","journal-title":"J. Neurol."},{"key":"44163_CR22","doi-asserted-by":"publisher","first-page":"e40700","DOI":"10.1097\/MD.0000000000040700","volume":"103","author":"J Zhou","year":"2024","unstructured":"Zhou, J., Yu, W., Ding, S., Shi, C. & Liang, H. Resolution of acute motor axonal neuropathy in a patient after treatment with efgartigimod: A case report. Med. (Baltim). 103, e40700. https:\/\/doi.org\/10.1097\/MD.0000000000040700 (2024).","journal-title":"Med. (Baltim)."},{"key":"44163_CR23","doi-asserted-by":"publisher","first-page":"3646","DOI":"10.1111\/ene.16073","volume":"30","author":"PA van Doorn","year":"2023","unstructured":"van Doorn, P. A. et al. European Academy of Neurology\/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barre syndrome. Eur. J. Neurol. 30, 3646\u20133674. https:\/\/doi.org\/10.1111\/ene.16073 (2023).","journal-title":"Eur. J. Neurol."},{"key":"44163_CR24","doi-asserted-by":"publisher","first-page":"e70064","DOI":"10.1111\/jns.70064","volume":"30","author":"RAC Hughes","year":"2025","unstructured":"Hughes, R. A. C., Cornblath, D. R., Jacobs, B. C. & van Doorn, P. A. Guillain-Barre Syndrome Disability Scale. J. Peripher Nerv. Syst. 30, e70064. https:\/\/doi.org\/10.1111\/jns.70064 (2025).","journal-title":"J. Peripher Nerv. Syst."},{"key":"44163_CR25","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/mus.24207","volume":"50","author":"A Breiner","year":"2014","unstructured":"Breiner, A., Barnett, C. & Bril, V. INCAT disability score: a critical analysis of its measurement properties. Muscle Nerve. 50, 164\u2013169. https:\/\/doi.org\/10.1002\/mus.24207 (2014).","journal-title":"Muscle Nerve"},{"key":"44163_CR26","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/mus.880141111","volume":"14","author":"RP Kleyweg","year":"1991","unstructured":"Kleyweg, R. P., van der Meche, F. G. & Schmitz, P. I. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barre syndrome. Muscle Nerve. 14, 1103\u20131109. https:\/\/doi.org\/10.1002\/mus.880141111 (1991).","journal-title":"Muscle Nerve"},{"key":"44163_CR27","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1212\/01.wnl.0000258673.31824.61","volume":"68","author":"M Mori","year":"2007","unstructured":"Mori, M., Kuwabara, S., Fukutake, T. & Hattori, T. Intravenous immunoglobulin therapy for Miller Fisher syndrome. Neurology 68, 1144\u20131146. https:\/\/doi.org\/10.1212\/01.wnl.0000258673.31824.61 (2007).","journal-title":"Neurology"},{"key":"44163_CR28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/jns.12194","volume":"22","author":"AI Davidson","year":"2017","unstructured":"Davidson, A. I. et al. Inhibition of complement in Guillain-Barre syndrome: the ICA-GBS study. J. Peripher Nerv. Syst. 22, 4\u201312. https:\/\/doi.org\/10.1111\/jns.12194 (2017).","journal-title":"J. Peripher Nerv. Syst."},{"key":"44163_CR29","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/s1474-4422(18)30114-5","volume":"17","author":"S Misawa","year":"2018","unstructured":"Misawa, S. et al. Safety and efficacy of eculizumab in Guillain-Barr\u00e9 syndrome: a multicentre, double-blind, randomised phase 2 trial. Lancet Neurol. 17, 519\u2013529. https:\/\/doi.org\/10.1016\/s1474-4422(18)30114-5 (2018).","journal-title":"Lancet Neurol."},{"key":"44163_CR30","doi-asserted-by":"publisher","first-page":"e70308","DOI":"10.1111\/ene.70308","volume":"32","author":"P Ripellino","year":"2025","unstructured":"Ripellino, P. et al. Efgartigimod as Add-On Treatment in Refractory Guillain-Barre Syndrome: A Case Report. Eur. J. Neurol. 32, e70308. https:\/\/doi.org\/10.1111\/ene.70308 (2025).","journal-title":"Eur. J. Neurol."},{"key":"44163_CR31","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/s0161-5890(96)00078-8","volume":"33","author":"TC Thomas","year":"1996","unstructured":"Thomas, T. C. et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol. Immunol. 33, 1389\u20131401. https:\/\/doi.org\/10.1016\/s0161-5890(96)00078-8 (1996).","journal-title":"Mol. Immunol."},{"key":"44163_CR32","doi-asserted-by":"publisher","first-page":"175628642513147","DOI":"10.1177\/17562864251314746","volume":"18","author":"S Chen","year":"2025","unstructured":"Chen, S., Ou, R., Wei, Q., Zhao, B. & Chen, X. Sequential administration of efgartigimod shortened the course of Guillain-Barre syndrome: a case series. Ther. Adv. Neurol. Disord. 18, 17562864251314746. https:\/\/doi.org\/10.1177\/17562864251314746 (2025).","journal-title":"Ther. Adv. Neurol. Disord"},{"key":"44163_CR33","doi-asserted-by":"publisher","first-page":"1586663","DOI":"10.3389\/fimmu.2025.1586663","volume":"16","author":"M Deng","year":"2025","unstructured":"Deng, M., Kong, Z., Wang, Y., Wang, X. & Li, T. Efgartigimod in the treatment of Guillain-Barre syndrome: case report. Front. Immunol. 16, 1586663. https:\/\/doi.org\/10.3389\/fimmu.2025.1586663 (2025).","journal-title":"Front. Immunol."},{"key":"44163_CR34","doi-asserted-by":"publisher","first-page":"e70072","DOI":"10.1111\/jns.70072","volume":"30","author":"H Cai","year":"2025","unstructured":"Cai, H. et al. Intravenous Efgartigimod or Intravenous Immunoglobulin in Guillain-Barre Syndrome: An Observational Multicenter Study. J. Peripher Nerv. Syst. 30, e70072. https:\/\/doi.org\/10.1111\/jns.70072 (2025).","journal-title":"J. Peripher Nerv. Syst."},{"key":"44163_CR35","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/s1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard, J. F. Jr. et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 20, 526\u2013536. https:\/\/doi.org\/10.1016\/s1474-4422(21)00159-9 (2021).","journal-title":"Lancet Neurol."},{"key":"44163_CR36","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/ajh.25680","volume":"95","author":"AC Newland","year":"2020","unstructured":"Newland, A. C. et al. Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. Am. J. Hematol. 95, 178\u2013187. https:\/\/doi.org\/10.1002\/ajh.25680 (2020).","journal-title":"Am. J. Hematol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44163-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44163-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44163-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:26:54Z","timestamp":1781641614000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44163-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["44163"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-44163-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"2 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Review Board of Zhejiang Provincial People\u2019s Hospital (Approval Number: KY2025005 ).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"It was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"14128"}}